AVANIR Pharmaceuticals to Announce Second Fiscal Quarter 2002 Results on May 13
Following the release, management will host a conference call with a simultaneous webcast at 1:30 p.m. Pacific/ 4:30 p.m. Eastern to discuss second fiscal quarter 2002 operating performance and outlook. The webcast will feature President and Chief Executive Officer Gerald J. Yakatan, Ph.D., Vice President and Chief Financial Officer Gregory Hanson and Xenerex Biosciences President and Chief Operating Officer J. David Hansen, and will be available live via the Internet by accessing AVANIR's web site at www.avanir.com . Individual investors can also listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel (available to AOL subscribers), Fidelity Investments(R) (Fidelity.com) and others. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents ( www.streetevents.com ).
For those who cannot listen to the live broadcast, the online replays will be available for 90 days, or a phone replay will be available through May 20, 2002, by dialing 888-266-2086 or 703-925-2435 and entering the passcode 5989450.
AVANIR Pharmaceuticals, based in San Diego, is a biopharmaceutical drug discovery and development company with an FDA-approved product. AVANIR is engaged in research, discovery, development and licensing of innovative drug products and, through its subsidiary Xenerex Biosciences, antibody generation services and antibody product development. The Company's next potential product, Neurodex, for the treatment of central nervous system disorders is currently in a Phase II/III clinical trial. The Company's website is http://www.avanir.com .
AVANIR press releases, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.
For further information please contact: Kristen McNally, General Information, +1-310-407-6548, firstname.lastname@example.org, or Tricia Ross, Analyst/Investor, +1-310-407-6540, email@example.com, or Tim Grace, Media, +1-312-640-6667, firstname.lastname@example.org, both of FRB|Weber Shandwick, for AVANIR Pharmaceuticals; or Patrice Saxon, Investor Relations of AVANIR Pharmaceuticals, +1-858-622-5202, email@example.com
SOURCE AVANIR Pharmaceuticals
Kristen McNally, General Information, +1-310-407-6548,
firstname.lastname@example.org, or Tricia Ross, Analyst/Investor,
+1-310-407-6540, email@example.com, or Tim Grace, Media,
+1-312-640-6667, firstname.lastname@example.org, both of FRB|Weber Shandwick, for
AVANIR Pharmaceuticals; or Patrice Saxon, Investor Relations of AVANIR
Pharmaceuticals, +1-858-622-5202, email@example.com
/Company News On-Call: http://www.prnewswire.com/comp/509050.html
Copyright (C) 2002 PR Newswire. All rights reserved.